Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inovio Strikes First Partnership, In Emerging Markets, For Lead Product

Executive Summary

Inovio's new licensing deal for its most advanced pipeline asset gives the US firm not only its first partner for the cervical dysplasia vaccine but also a presence in a major emerging market.

Advertisement

Related Content

Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
China Approves First HPV Vaccine But Can GSK Secure Its Lead?
Genexine Raises New Funds To Progress Promising HPV, Other Projects

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel